Ben Ho Park, M.D., Ph.D.

Dr. Park attended The University of Chicago for his A.B. degree, followed by dual training at The University of Pennsylvania School of Medicine where he received both his M.D. and Ph.D. degrees. Dr. Park then trained in Internal Medicine and Hematology/Oncology at The University of Pennsylvania prior to completing a post-doctoral fellowship in the laboratory of Dr. Bert Vogelstein at Johns Hopkins. Dr. Park joined the faculty in the Breast Cancer Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 2002, and was Professor of Oncology, Associate Director of Education and Research Training and Associate Dean of Postdoctoral Affairs for the School of Medicine prior to joining Vanderbilt University Medical Center in 2018, where he was co-leader of the Breast Cancer Research Program, Associate Director for Translational Research, and Director of Precision Oncology. In 2020, he became Director of the Division of Hematology and Oncology, and in 2022 he was named Director of the Vanderbilt-Ingram Cancer Center. He is currently the Benjamin F. Byrd, Jr. Professor in Oncology and Professor of Medicine at Vanderbilt University Medical Center.
Dr. Park’s research program involves identifying and validating genetic targets for breast cancer therapy and diagnostics. In particular, Dr. Park has pioneered the use of “liquid biopsies” to help guide the management of breast cancer therapies. He has also led the formation and implementation of molecular tumor boards at Johns Hopkins and other institutions, and more recently at the Vanderbilt-Ingram Cancer Center regionally, nationally and internationally. He is Chief Medical Officer for the Global Cancer Institute, a Komen Scholar, a member of the scientific advisory board of the Breast Cancer Research Foundation, Co-Director of the Breast Cancer SPORE program at the Vanderbilt-Ingram Cancer Center, a member of the NCI Breast Steering Committee, and a founding member of the NCI Center to Reduce Cancer Health Disparities (CRCHD) Cancer Equity Leaders (CEL).